UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF
THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER
SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 001-38707

 

LogicBio Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

65 Hayden Avenue,

2nd Floor
Lexington, MA 02421

(617) 245-0399

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive
offices)

 

Common Stock, par value $0.0001 per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

  Rule 12g-4(a)(1) x        
  Rule 12g-4(a)(2) ¨        
  Rule 12h-3(b)(1)(i) x        
  Rule 12h-3(b)(1)(ii) ¨        
  Rule 15d-6 ¨        
  Rule 15d-22(b) ¨        

 

Approximate number of holders of record as of the certification or notice date: one (1).

  

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, LogicBio Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: November 29, 2022   LogicBio Therapeutics, INC.
         
      By: /s/ David E. White
      Name: David E. White
      Title: Treasurer

 

 

LogicBio Therapeutics (NASDAQ:LOGC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more LogicBio Therapeutics Charts.
LogicBio Therapeutics (NASDAQ:LOGC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more LogicBio Therapeutics Charts.